Get the Stockscreener App
8.70
1.05%
0.09
Pre-market:
8.71
0.01
+0.11%
Immunitybio Inc stock is traded at $8.70, with a volume of 45.15M.
It is up +1.05% in the last 24 hours and up +34.26% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$8.61
Open:
$8.63
24h Volume:
45.15M
Relative Volume:
1.61
Market Cap:
$8.57B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-8.9691
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
+46.34%
1M Performance:
+34.26%
6M Performance:
+284.96%
1Y Performance:
+139.01%
1-Day Range:
$8.32
$9.25
1-Week Range:
$5.93
$9.25
52-Week Range:
$1.83
$9.25
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.70 | 8.48B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.90 | 119.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
779.67 | 82.71B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
844.41 | 52.43B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
336.19 | 45.01B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
362.14 | 39.23B | 4.98B | 69.60M | 525.67M | 0.5198 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
IBRX Stock To Open Week On A High? Chairman Teases Anktiva’s 3-Year Expansion Plans, Hints At Cancer Breakthrough - Stocktwits
ImmunityBio (IBRX) soars to new high on Anktiva future expansion - MSN
Top Biotech Stocks To Keep An Eye OnFebruary 21st - MarketBeat
ImmunityBio, Inc. $IBRX Stock Holdings Lifted by Skandinaviska Enskilda Banken AB publ - MarketBeat
ImmunityBio (NASDAQ:IBRX) Stock Price Up 1%Here's Why - MarketBeat
ImmunityBio Inc. (IBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ImmunityBio partners with distributors to launch Anktiva in Saudi Arabia By Investing.com - Investing.com Nigeria
ImmunityBio wins EU nod for bladder cancer combo therapy, stock up - MSN
IBRX Stock Rally Not Over Yet? Chairman Says Trump Diplomacy Led To ‘Amazing Results’ For Cancer Drug - Stocktwits
ImmunityBio Stock Surges on Bold Global Expansion - TipRanks
ImmunityBio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts - Asianet Newsable
ImmunityBio to launch ANKTIVA® in Saudi Arabia for bladder and lung cancer treatment - BioSpectrum Asia
ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients - BioSpace
ImmunityBio partners with distributors to launch Anktiva in Saudi Arabia - Investing.com
ImmunityBio Taps 85-Person Sales Team to Launch Its Bladder Cancer Drug In European Countries - Bitget
ImmunityBio to Launch Anktiva in Saudi Arabia Through Biopharma, Cigalah Healthcare Partnership - marketscreener.com
ImmunityBio, Inc. has partnered with Biopharma and Cigalah Healthcare to officially launch its innovative therapy Anktiva® in the Saudi Arabian market. - Bitget
ImmunityBio stock steadies near a 52-week high as EU clears ANKTIVA; Accord rollout plan in focus - Bez Kabli
Immunitybio Inks Partnerships To Launch Cancer Drug In Saudi Arabia Amid Expansion Efforts - Menafn.com
ImmunityBio Wins EU Nod for Bladder Cancer Combo Therapy, Stock Up - The Globe and Mail
Conditional Approval for ANKTIVA in BCG-Unresponsive Non-Muscle Invasive Bladder CancerImmunityBio - Oncodaily
European Approval Ignites Surge for ImmunityBio Shares - AD HOC NEWS
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch - BioSpace
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc.IBRX - PR Newswire
ImmunityBio Wins EU Anktiva Nod As Investors Weigh Execution Risks - simplywall.st
ImmunityBio Stock Soars 42% After New Anktiva Approvals. Here’s What’s Driving the Rally - TIKR.com
ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsi - PharmiWeb.com
ImmunityBio partners with Accord Healthcare to expand ANKTIVA across Europe - Investing.com Australia
IMMUNITYBIO, INC. (IBRX) Stock, Price, News, Quotes, Forecast and Insights - MSN
ImmunityBio Holds Golden Cross As Stock Trades 170% Above 200-Day Average - Bitget
ImmunityBio Stock Maintains Golden Cross Signal - Intellectia AI
ImmunityBio (NASDAQ:IBRX) Shares Gap DownShould You Sell? - MarketBeat
Regulatory Challenges Impact ImmunityBio Shares - timothysykes.com
ImmunityBio, Accord Healthcare Collaborate to Expand Anktiva Access in Europe - marketscreener.com
ImmunityBio Partners with Accord Healthcare to Expand Anktiva Access - Intellectia AI
ImmunityBio (IBRX): The Rise of Immunotherapy 2.0 and the Global Expansion of ANKTIVA - The Chronicle-Journal
ImmunityBio Announces Partnership To Expand Access To Anktiva Across 30 Countries - Stocktwits
ImmunityBio, Inc. announces the expansion of access to its innovative drug Anktiva® in the EU through a new distribution partnership, while officially establishing an Irish subsidiary to provide strategic support for the comprehensive promotion of its products in - Bitget
ImmunityBio inks deal for Anktiva access in Europe (IBRX:NASDAQ) - Seeking Alpha
ImmunityBio (IBRX) Stock Jumps as ANKTIVA Becomes First Approved Bladder Cancer Immunotherapy in Europe - MEXC
in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch - Business Wire
ImmunityBio (IBRX) Stock Jumps as EU Clears ANKTIVA for Bladder Cancer - Blockonomi
ImmunityBio (IBRX) Is Up 29.0% After EU Clears First ANKTIVA+BCG Immunotherapy For NMIBC CIS - Yahoo Finance
ImmunityBio (IBRX) Soars to New High on Anktiva Future Expansion - Bitget
ImmunityBio’s EU Anktiva Nod Sparks Questions On Valuation And Momentum - Yahoo Finance
ImmunityBio (IBRX) Moves 41.9% Higher: Will This Strength Last? - Nasdaq
Immunitybio Announces Partnership To Expand Access To Anktiva Across 30 Countries - Menafn.com
ImmunityBio Soars Over 40% as European Commission Approves Bladder Cancer Drug Anktiva - NAI500
Institution Moves: Does ImmunityBio Inc have a sustainable dividendTake Profit & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Why IBRX Stock Became A High-Stakes Showdown Between Shorts And Retail Bulls - Stocktwits
ImmunityBio's Short Interest Turns Bullish Ahead of EU Decision - Intellectia AI
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.34%
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):